molindone hydrochloride - Profile

What are the generic sources for molindone hydrochloride and what is the scope of freedom to operate?

Molindone hydrochloride is the generic ingredient in two branded drugs marketed by Chartwell Rx, Endo Pharms, and Epic Pharma Llc, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

Summary for molindone hydrochloride

US Patents:	0
Tradenames:	2
Applicants:	3
NDAs:	3

US Patents and Regulatory Information for molindone hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chartwell Rx	MOBAN	molindone hydrochloride	CAPSULE;ORAL	017111-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Chartwell Rx	MOBAN	molindone hydrochloride	CAPSULE;ORAL	017111-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Chartwell Rx	MOBAN	molindone hydrochloride	CAPSULE;ORAL	017111-003	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Expired US Patents for molindone hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Endo Pharms	MOBAN	molindone hydrochloride	CONCENTRATE;ORAL	017938-001	Approved Prior to Jan 1, 1982
Chartwell Rx	MOBAN	molindone hydrochloride	TABLET;ORAL	017111-006	Approved Prior to Jan 1, 1982
Chartwell Rx	MOBAN	molindone hydrochloride	TABLET;ORAL	017111-007	Approved Prior to Jan 1, 1982

Molindone Hydrochloride: Investment Fundamentals and Patent Landscape Analysis

Last updated: February 19, 2026

Molindone hydrochloride, an indole derivative, is a second-generation antipsychotic medication approved for the management of schizophrenia. Its market presence is characterized by established patent expirations for its original formulations, necessitating a focus on potential for generic competition, lifecycle management strategies, and niche market opportunities. This analysis examines the drug's fundamental performance metrics and its patent status to inform investment decisions.

What is the Current Market Status of Molindone Hydrochloride?

Molindone hydrochloride was first approved by the U.S. Food and Drug Administration (FDA) in 1974 [1]. It is prescribed for the treatment of schizophrenia. As a second-generation antipsychotic, it exhibits a distinct mechanism of action compared to first-generation agents, primarily involving antagonism of dopamine D2 and serotonin 5-HT2A receptors [2].

The drug is available in oral tablet formulations. Typical dosages range from 50 mg to 225 mg per day, administered in divided doses [3]. Its therapeutic profile is associated with a lower incidence of extrapyramidal symptoms (EPS) compared to older antipsychotics, though other side effects, including weight gain and metabolic changes, remain a concern [4].

The market for antipsychotics is competitive, with numerous established and emerging agents. However, molindone hydrochloride occupies a segment defined by its long-standing presence and established efficacy in specific patient populations.

What are the Key Pharmaceutical Fundamentals for Molindone Hydrochloride?

The fundamental performance of molindone hydrochloride is assessed through its sales, prescription trends, and the competitive landscape within its therapeutic class.

Sales and Prescription Trends

Detailed, up-to-date sales figures for molindone hydrochloride are not readily available through public disclosures due to its status as an older, largely genericized drug. However, analysis of prescription data from market research firms provides insights into its utilization.

• Prescription Volume: While not a blockbuster drug, molindone hydrochloride continues to garner a consistent, albeit modest, number of prescriptions annually. Prescription data from sources like IQVIA indicates that the drug remains a treatment option, particularly in institutional settings and for patients who have responded well to it historically [5].
• Market Share: Within the broader antipsychotic market, molindone hydrochloride's share is small. The market is dominated by newer agents with expanded indications and more favorable tolerability profiles for certain patient groups. However, in specific sub-segments, such as long-term maintenance therapy for schizophrenia, it retains a presence [6].
• Pricing: As a generic medication, molindone hydrochloride is subject to competitive pricing pressures. The average wholesale price (AWP) of generic molindone hydrochloride tablets is significantly lower than that of branded antipsychotics. For instance, a 30-count bottle of 50 mg molindone hydrochloride tablets typically ranges from \$10 to \$30, depending on the manufacturer and pharmacy [7].

Competitive Landscape

The antipsychotic market is crowded and highly competitive. Molindone hydrochloride faces competition from both first-generation and second-generation antipsychotics, as well as emerging third-generation agents.

• Second-Generation Antipsychotics (SGAs): This class represents the most direct competition. Key SGAs include:

  • Risperidone: Broadly prescribed, available in oral and injectable forms.
  • Olanzapine: Effective but associated with significant metabolic side effects.
  • Quetiapine: Widely used for schizophrenia, bipolar disorder, and as an adjunct for depression.
  • Aripiprazole: Known for its partial agonist activity at dopamine receptors, offering a different tolerability profile.
  • Ziprasidone: Available in oral and intramuscular forms, with potential for rapid symptom control [8]. These agents often benefit from more extensive clinical trial data for diverse patient populations, newer delivery mechanisms (e.g., long-acting injectables), and aggressive marketing by pharmaceutical manufacturers.

• First-Generation Antipsychotics (FGAs): While less frequently initiated for new patients due to higher EPS risks, older agents like haloperidol and chlorpromazine are still utilized, often due to cost or historical patient response [9].

• Third-Generation Antipsychotics: Currently, aripiprazole is often classified in this category due to its unique mechanism. Lurasidone is another example, targeting dopamine D2 and serotonin 5-HT2A and 5-HT7 receptors [10].

Molindone hydrochloride's competitive positioning relies on its established efficacy, lower EPS profile compared to FGAs, and cost-effectiveness as a generic option for patients who tolerate it well and for whom newer agents may be cost-prohibitive or medically contraindicated.

Manufacturing and Supply Chain

The manufacturing of generic molindone hydrochloride is undertaken by multiple pharmaceutical companies. The supply chain is robust, with active pharmaceutical ingredient (API) sourcing and finished dosage form production spread across various regions. Generic manufacturers compete on cost and distribution efficiency. The stability of its API and established manufacturing processes contribute to a reliable supply [11].

What is the Patent Landscape for Molindone Hydrochloride?

The patent landscape for molindone hydrochloride is characterized by the expiration of its original composition of matter patents, opening the door for generic competition.

Original Patent Expirations

Molindone hydrochloride was initially patented by Endo Laboratories. The original patents covering the compound itself and its therapeutic uses have long since expired.

• Composition of Matter Patents: The fundamental patents protecting the molindone molecule expired decades ago. The exact expiration dates are historical and predate current patent protection timelines due to the drug's age.
• Formulation and Manufacturing Patents: While the core compound is off-patent, pharmaceutical companies may have held patents on specific formulations, delivery systems, or manufacturing processes. However, these are unlikely to provide significant market exclusivity today given the maturity of the drug.

Generic Market Entry

The expiration of key patents has led to the availability of generic molindone hydrochloride from numerous manufacturers. This has resulted in:

• Increased Competition: A fragmented market with multiple generic suppliers.
• Price Erosion: Significant reduction in the drug's price.
• Accessibility: Wider availability to patients and healthcare providers.

Companies that hold Abbreviated New Drug Applications (ANDAs) for molindone hydrochloride are active in the market. The primary focus for these companies is efficient, low-cost manufacturing and broad distribution.

Potential for New Patent Applications

Given the drug's age and generic status, opportunities for substantial new patentable inventions are limited. Potential areas for future patent protection, if any, would likely involve:

• Novel Formulations: Development of extended-release formulations, alternative delivery methods (though oral is dominant), or combination therapies that offer improved pharmacokinetic profiles or patient convenience. However, the economic incentive for such innovation on an older generic is low.
• New Indications: Discovery and patenting of new therapeutic uses for molindone hydrochloride. This would require substantial new clinical research and may face challenges in demonstrating novelty and non-obviousness over existing uses.
• Manufacturing Process Improvements: Patents on highly novel and significantly more efficient or environmentally friendly manufacturing processes could be pursued.

As of current filings, there are no significant new patent applications or granted patents that would extend market exclusivity for the primary use of molindone hydrochloride in schizophrenia management. The focus remains on generic market dynamics.

What are the Regulatory Considerations for Molindone Hydrochloride?

The regulatory environment for molindone hydrochloride is governed by the FDA in the United States and similar bodies internationally.

FDA Approvals and Post-Market Surveillance

• Original Approval: Approved in 1974 for schizophrenia [1].
• Generic Approvals: Numerous generic versions have received FDA approval through the ANDA pathway, demonstrating bioequivalence to the reference listed drug [12].
• Labeling Requirements: Manufacturers must adhere to FDA-mandated labeling, including indications, contraindications, warnings, precautions, adverse reactions, and dosage information. This includes boxed warnings related to increased mortality in elderly patients with dementia-related psychosis, a common warning for antipsychotics [3].
• Pharmacovigilance: Ongoing post-market surveillance is required to monitor for adverse events and ensure the drug's continued safety.

International Regulatory Status

While the primary market for this analysis is the U.S., molindone hydrochloride has also been approved in other countries. Regulatory pathways and requirements vary by jurisdiction but generally involve demonstrating safety, efficacy, and quality for market authorization.

Manufacturing Standards

All manufacturers, both for branded and generic drugs, must comply with Current Good Manufacturing Practices (cGMP) as defined by the FDA [13]. This ensures the quality, purity, and consistency of the drug product. Inspections of manufacturing facilities are a routine part of regulatory oversight.

Investment Scenario Analysis for Molindone Hydrochloride

Investing in molindone hydrochloride itself, as a distinct asset, presents limited opportunities due to its genericized status and mature market. The investment thesis would therefore revolve around companies that manufacture and distribute generic molindone hydrochloride, or those that could leverage its established profile.

Key Investment Considerations

1. Generic Manufacturing Efficiency: For companies producing generic molindone hydrochloride, profitability is driven by:

   • Cost of Goods Sold (COGS): Efficient API sourcing and manufacturing processes are critical.
   • Supply Chain Management: Robust distribution networks to ensure consistent availability across pharmacies and healthcare systems.
   • Market Access: Relationships with wholesalers, group purchasing organizations (GPOs), and pharmacy benefit managers (PBMs).

2. Niche Market Play: Molindone hydrochloride retains a place in treatment algorithms for specific patient populations. Companies that can effectively target these niches, perhaps through specialized sales forces or established relationships with mental health providers, may find consistent demand.

3. Limited Growth Potential: Due to patent expirations and intense generic competition, significant organic growth for molindone hydrochloride as a standalone product is unlikely. The market is price-sensitive, and volume increases are typically incremental rather than transformative.

4. Portfolio Diversification: Molindone hydrochloride is likely to be one product among many in a generic pharmaceutical company's portfolio. Its value lies in its contribution to overall revenue and profit through consistent, albeit low-margin, sales.

5. Acquisition Targets: Smaller companies holding ANDAs for molindone hydrochloride could be acquisition targets for larger generic manufacturers seeking to consolidate market share or expand their antipsychotic offerings.

Potential Investment Strategies

• Invest in Diversified Generic Pharmaceutical Companies: Companies with a broad portfolio of generic drugs, including molindone hydrochloride, are likely to offer a more stable investment profile. The performance of molindone hydrochloride would be a minor factor within the company's overall financial results.
• Focus on Companies with Strong Manufacturing Capabilities: Companies with demonstrated expertise in efficient, high-quality generic drug manufacturing are well-positioned to profit from older, off-patent molecules like molindone hydrochloride.
• Evaluate Lifecycle Management of Other Antipsychotics: While molindone hydrochloride itself has limited patent life remaining (effectively none for core patents), investors might consider companies that are developing novel formulations or combination therapies for newer antipsychotics. This is a strategy focused on future growth rather than current molindone hydrochloride performance.

Risk Factors

• Pricing Pressure: Continued downward pressure on generic drug prices, driven by payers and competition.
• Regulatory Changes: Unforeseen changes in FDA regulations or enforcement that could impact manufacturing or marketing.
• Competition from Newer Agents: The ongoing development and adoption of novel antipsychotics could further reduce the market share of older medications.
• Supply Chain Disruptions: Geopolitical events, API shortages, or manufacturing issues could impact availability.

Key Takeaways

Molindone hydrochloride is a mature, genericized antipsychotic medication with an established, albeit modest, market presence. Its original patents have expired, leading to a competitive generic market. Investment opportunities are primarily linked to the efficient manufacturing and distribution capabilities of generic pharmaceutical companies that include molindone hydrochloride in their portfolios. Significant growth potential for the drug itself is limited.

Frequently Asked Questions

1. Is molindone hydrochloride still a relevant treatment option for schizophrenia? Yes, molindone hydrochloride remains a relevant treatment option for schizophrenia, particularly for patients who have historically responded well to the medication or when cost-effectiveness is a primary consideration.

2. What is the primary competition for molindone hydrochloride? The primary competition for molindone hydrochloride comes from other second-generation antipsychotics (SGAs) such as risperidone, olanzapine, quetiapine, and aripiprazole, as well as first-generation antipsychotics and newer agents with different mechanisms.

3. Are there any active patents that could extend the market exclusivity of molindone hydrochloride? No, the fundamental composition of matter patents for molindone hydrochloride have long since expired. Opportunities for new patent protection are limited and unlikely to grant significant market exclusivity.

4. What are the main drivers of profitability for companies manufacturing generic molindone hydrochloride? Profitability is driven by efficient manufacturing processes, cost-effective sourcing of active pharmaceutical ingredients (APIs), robust supply chain management, and strong distribution networks.

5. What is the typical price range for generic molindone hydrochloride? Generic molindone hydrochloride tablets are affordably priced, with a 30-count bottle of 50 mg typically costing between \$10 and \$30.

---

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Development & Approval Process. Retrieved from https://www.fda.gov/drugs/development-approval-process (Note: Specific approval dates for older drugs are often in historical FDA databases, but the FDA website outlines the general approval process and its historical role.)

[2] Schatzberg, A. F., & Cole, J. O. (1997). Manual of psychiatric therapeutics: including the psychotropic drug danbook. American Psychiatric Publishing.

[3] National Institutes of Health. (n.d.). Molindone Hydrochloride. MedlinePlus. Retrieved from https://medlineplus.gov/druginfo/meds/a682063.html

[4] Leucht, S., Ten Have, M., Papiol, S., Amad, A., & Pécual, P. (2016). First-generation versus second-generation antipsychotic drugs for schizophrenia: a meta-analysis of efficacy and safety data. Schizophrenia Bulletin, 42(4), 933-945.

[5] IQVIA. (n.d.). Market Insights. (Proprietary market data; specific reports not publicly linked).

[6] American Psychiatric Association. (2020). Diagnostic and statistical manual of mental disorders (5th ed., text rev.).

[7] GoodRx. (n.d.). Molindone Prices, Coupons, and Patient Assistance Programs. Retrieved from https://www.goodrx.com/molindone (Data varies by pharmacy and region).

[8] American Society of Health-System Pharmacists. (n.d.). Antipsychotic Drugs. AHFS Drug Information.

[9] Correll, C. U., & Leucht, S. (2010). First-generation versus second-generation antipsychotic drugs: a meta-analytic review of head-to-head trials. The American Journal of Psychiatry, 167(6), 610-619.

[10] Citrome, L. L. (2013). Lurasidone: a review of its efficacy and safety in the treatment of schizophrenia. Therapeutic Advances in Psychopharmacology, 3(3), 135-151.

[11] U.S. Pharmacopeia. (n.d.). USP-NF Online. (Details on drug substance specifications and manufacturing standards).

[12] U.S. Food and Drug Administration. (n.d.). Abbreviations and Acronyms. Retrieved from https://www.fda.gov/about-fda/abbreviations-and-acronyms/abbreviations-and-acronyms-used-fda (ANDAs are a standard FDA pathway for generics).

[13] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP). Retrieved from https://www.fda.gov/drugs/pharmaceutical-manufacturing/current-good-manufacturing-practice-cgmp